05:07 AM EDT, 08/06/2026 (MT Newswires) -- Fusion Antibodies (FAB.L) received a notice of allowance from IP Australia for a patent application covering two families of antibodies and methods for designing antibody libraries, according to a Thursday release. The UK-listed preclinical antibody discovery company said the patent, once granted, is expected to complement its offering of Opti-designed antibody libraries for applications including antibody discovery, affinity maturation and sequence optimization. Fusion Antibodies added that it continues to pursue patent applications for its OptiMAL Library in several other jurisdictions, including Europe and China.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.